1,039
Participants
Start Date
March 12, 2015
Primary Completion Date
September 13, 2016
Study Completion Date
August 1, 2017
THS 2.2
Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
CC
Ad libitum use of CC in an ambulatory setting for 26 weeks
National Clinical Research, Richmond
PMG Research of Cary, Cary
PMG Research of Raleigh, Raleigh
PMG Research of Charlotte, Charlotte
PMG Research of Wilmington, Wilmington
Covance, Inc, Daytona Beach
Compass Research, The Villages
Compass Research, Orlando
Clinical Research West Florida, Tampa
Clinical Research West Florida, Clearwater
PMG Research of Bristol, Bristol
NOCCR, Knoxville
Central Kentucky Research Associate, Lexington
Midwest Clinical Research Center, Dayton
Celerion Lincoln, Lincoln
Benchmark, Fort Worth
Benchmark, San Angelo
Benchmark, Austin
Celerion Arizona, Tempe
Philip Morris Products S.A.
INDUSTRY